Terra Alpha Investments LLC Has $1.13 Million Holdings in Edwards Lifesciences Corporation $EW

Terra Alpha Investments LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 39.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,283 shares of the medical research company’s stock after selling 8,767 shares during the quarter. Terra Alpha Investments LLC’s holdings in Edwards Lifesciences were worth $1,132,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after acquiring an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after purchasing an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp grew its holdings in shares of Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after purchasing an additional 11,384 shares during the last quarter. Washington Trust Advisors Inc. grew its holdings in shares of Edwards Lifesciences by 15.6% during the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock worth $10,156,000 after purchasing an additional 17,625 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Piper Sandler restated an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Wells Fargo & Company increased their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Finally, Evercore restated an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.65.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president owned 33,934 shares in the company, valued at $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 88,096 shares of company stock worth $7,288,799 over the last 90 days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $81.34 on Friday. The business’s 50-day simple moving average is $81.50 and its 200 day simple moving average is $82.86. The stock has a market cap of $46.84 billion, a price-to-earnings ratio of 43.27, a P/E/G ratio of 2.04 and a beta of 0.87. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $87.89. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.